SERIES B-2 PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • August 14th, 2017 • Capstone Therapeutics Corp. • Pharmaceutical preparations • Delaware
This Series B-2 Preferred Stock Purchase Agreement (this “Agreement”) is made and entered into as of August 11, 2017, by and among LipimetiX Development, Inc., a Delaware corporation (the “Company”), and Capstone Therapeutics Corp., a Delaware corporation (the “Purchaser”).
JOINDER AND COUNTERPART SIGNATURE PAGE OF REGISTRATION RIGHTS AGREEMENT OF LIPIMETIX DEVELOPMENT, INC.Joinder and Counterpart Signature • August 14th, 2017 • Capstone Therapeutics Corp. • Pharmaceutical preparations
As of August 11, 2017, the undersigned has executed this counterpart signature to the Registration Rights Agreement entered into as of August 25, 2016, by and among the Company, the Common Holders and the Investors (as such terms are defined therein), and does hereby agree to be bound by all of the obligations as an “Investor” thereunder and the terms thereof as though originally an Investor thereto.
AMENDED AND RESTATED STOCKHOLDERS AGREEMENT OFStockholders Agreement • August 14th, 2017 • Capstone Therapeutics Corp. • Pharmaceutical preparations
This FIRST AMENDMENT TO THE AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (the “First Amendment”) is entered into to be effective as of August 11, 2017 (the “Effective Date”) by and among LipimetiX Development, Inc., a Delaware corporation (the “Company”), and the stockholders executing this First Amendment below representing the Required Holders (as defined below).
